Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.47 |
| ▸ | RXRB | P28702 | 13/20 | 0.47 |
| ▸ | RXRG | P48443 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212387 | 0.89 | KDM4E (0.38) | RXRARXRBRXRGALDH1A1KMT2A | |
| SCHEMBL5211801 | 0.84 | TACR1 (0.43) | MAPT | |
| SCHEMBL5210892 | 0.80 | RXRA (0.62) | RXRARXRBRXRGALDH1A1NR4A2 | |
| SCHEMBL5210730 | 0.80 | RXRA (0.53) | RXRARXRBRXRGALDH1A1NR4A2 | |
| SCHEMBL5210928 | 0.79 | RXRA (0.46) | RXRARXRBRXRGALDH1A1HDAC6 | |
| SCHEMBL5214453 | 0.78 | CNR2 (0.38) | NR1H2MAPT | |
| SCHEMBL5214457 | 0.78 | NR1H2 (0.40) | ALDH1A1NR1H2KMT2AKDM4EMAPT | |
| SCHEMBL5206931 | 0.76 | RXRA (0.51) | RXRARXRBRXRGALDH1A1NR4A2 | |
| SCHEMBL5213169 | 0.75 | RXRA (0.49) | RXRARXRBRXRGALDH1A1NR4A2 | |
| SCHEMBL5210210 | 0.74 | PTGS2 (0.31) | KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | RXRA 1231/4885RXRB 1269/4885RXRG 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.